If Your DNA Trains an AI That Finds a Blockbuster Drug, Who Gets Paid?
Who owns genetic data once it trains an AI model? We look at the law, the 23andMe bankruptcy, UK Biobank, the Cali Fund and benefit sharing to find out who profits.
7 articles filed here
A new Developing World Bioethics paper applies six Yoruba moral principles to AI and big-data health research, and proposes concrete governance machinery.
Who owns genetic data once it trains an AI model? We look at the law, the 23andMe bankruptcy, UK Biobank, the Cali Fund and benefit sharing to find out who profits.
Informed consent was designed for human clinicians. New 2025 and 2026 evidence shows what AI consent forms leave out, what patients want to hear, and what could fix it.
UK Biobank's Research Analysis Platform reopens this September after a data security incident, and a 2026 study shows why AI is quietly eroding old promises of genetic anonymity.
RAND says no single safeguard can stop AI-assisted bioweapons, and lays out nine layered defences. Here is what the report argues, why it lands now, and where it is still guesswork.
The August 2026 American Journal of Bioethics issue confronts AI agents moving into clinical and research operations, and asks an uncomfortable question: what happens when those same agents start doing the work of bioethicists?
QED Science's AI ranked 57,455 bioRxiv preprints and named a 'top 1%'. Blinded experts sided with the machine over journal prestige in 75% of cases. We examine the evidence, the backlash, and what AI triage means for pandemic-era science.